Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen

AIDS. 1998 Aug 20;12(12):1483-90. doi: 10.1097/00002030-199812000-00010.

Abstract

Objectives and design: The dynamics uf viral decline following the initiation of antiretroviral treatment were studied in 29 HIV-1-infected patients participating in a two-arm trial comparing immediate (group A: ritonavir, zidovudine and lamivudine) and delayed (group B: ritonavir supplemented by zidovudine and lamivudine on day 21) triple therapy. Parameters underlying viral dynamics were estimated using mathematical models tailored to these treatment protocols.

Results: The decline in plasma HIV-1 density between day 0 and 21 was steeper in group A (-2.27+/- 0.46 log10) than group B (-1.87+/-0.56 log10). In a subset of patients amenable to full mathematical analysis, a short-lived productively infected cell compartment (producing approximately 97% of total virions) decayed with a half-life of 1.0-2.5 days, whereas a long-lived infected cell compartment decayed with a half-life of 18.8-32.8 days. Estimates for the time for the elimination of virus from these two cell populations ranged from 474 to 802 days. The rate of loss of productively infected CD4+ T cells was positively correlated with baseline viral load in group A and in the combined dataset.

Conclusions: These results suggest that HIV-infected cell populations may have a faster turnover in patients with higher viral loads due to higher infection rate parameters, higher rates of virus production, or lower virus clearance rates.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • CD4-Positive T-Lymphocytes
  • Drug Therapy, Combination
  • HIV Infections / drug therapy*
  • HIV-1 / physiology*
  • Humans
  • Lamivudine / administration & dosage
  • Lamivudine / therapeutic use
  • Models, Theoretical
  • RNA, Viral / analysis
  • Ritonavir / administration & dosage
  • Ritonavir / therapeutic use
  • Treatment Outcome
  • Viral Load*
  • Zidovudine / administration & dosage
  • Zidovudine / therapeutic use

Substances

  • Anti-HIV Agents
  • RNA, Viral
  • Lamivudine
  • Zidovudine
  • Ritonavir